About
.....
Leadship
The scientists and innovators driving Celliaz forward.
Kyung Hwa Kang, Ph.D
CEO & Management
- PhD, Chung-Ang University, Korea
- Post-Doc, UCSD, USA
- Principal Researcher, KAIST
- Research Professor, University of Basel, Switzerland
- Experts in neurodegenerative diseases and brain
- cancer stem cell research
Jin Woo Kim, Ph.D.
CSO & Science & Strategy
- PhD, KAIST, Korea
- Post-doc, Salk Institute, USA
- Endowed Chair Professor, KAIST
- Visiting scientist, FMI, Switzerland
- Expert in retinal development and regeneration
- Entrepreneurial technology inventor
Eun Jung Lee, Ph.D.
Head of R&D
- PhD, KAIST, Korea
- Post-doc & Research Professor, KAIST
- Expert in retinal regeneration
- Co-inventor of Anti-PROX1 therapeutics
Core Competencies
Vision Restoration
Moving beyond symptom control
to restore vision through
retinal regeneration.
CLZ001 Innovation
Developing first-in-class
therapies that remove biological
arriers to retinal repair.
Universal Applicability
Targeting regenerative
mechanisms rather than
individual mutations
Global Opportunity
Creating scalable regenerative therapies for patients worldwide.
Our Vision for the Future
A new Paradigm for
Vision Recovery
Celliaz is advancing a new generation of regenerative therapeutics
designed to restore vision rather than merely delay its loss.
Building on proprietary discoveries in retinal regeneration,
we continue to expand our platform technologies,
strengthen global partnerships, and accelerate the path toward clinical
development and commercialization.